Patents by Inventor Shuli You
Shuli You has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8293757Abstract: The invention provides compounds of formula (1) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR?, PDGFR?, CSF1R, AbI, BCR-AbI, CSK, JNK1, JNK2, p38, p70S6K, TGF?, SRC, EGFR, trkB, FGFR3. Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2?, BRK, Fms, KDR, c-rapor b-raf kinases.Type: GrantFiled: August 19, 2008Date of Patent: October 23, 2012Assignee: IRM LLCInventors: Valentina Molteni, Xiaolin Li, Xiaodong Liu, Donatella Chianelli, Juliet Nabakka, Jon Loren, Shuli You
-
Patent number: 8183248Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of Abl, Bcr-Abl, Bmx, BTK, b-RAF, c RAF, CSK, cSRC, Fes, FGFR3, Flt3, IKK?, IKK?, JNK1?1, JNK2?2, Lck, Met, MKK4, MKK6, p70S6K, PAK2, PDGFR?, PKA, PKC?, PKD2, ROCK-II, Ros, Rsk1, SAPK2?, SAPK2?, SAPK3, SAPK4, SGK, Syk, Tie2 and TrkB kinases.Type: GrantFiled: May 10, 2006Date of Patent: May 22, 2012Assignee: IRM LLCInventors: Advait Nagle, Nathanael Schiander Gray, Yi Liu, Pingda Ren, Taebo Sim, Shuli You
-
Publication number: 20110301175Abstract: The invention provides compounds of formula (1) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR?, PDGFR?, CSF1R, AbI, BCR-AbI, CSK, JNK1, JNK2, p38, p70S6K, TGF?, SRC, EGFR, trkB, FGFR3. Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2?, BRK, Fms, KDR, c-rapor b-raf kinases.Type: ApplicationFiled: August 19, 2008Publication date: December 8, 2011Inventors: Valentina Molteni, Xiaolin Li, Xiaodong Liu, Donatella Chianelli, Juliet Nabakka, Jon Loren, Shuli You
-
Patent number: 7745437Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, b-RAF, ??K, T??2, ???, ?NK2?2, MKK4, c-RAF, MKK6, SAPK2? and SAPK2? kinases.Type: GrantFiled: June 9, 2005Date of Patent: June 29, 2010Assignee: IRM LLCInventors: Pingda Ren, Xia Wang, Guobao Zhang, Qiang Ding, Shuli You, Qiong Zhang, Greg Chopiuk, Pamela A. Albaugh, Taebo Sim, Nathanael Schiander Gray
-
Publication number: 20100081656Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR?, PDGFR?, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGF?, SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2?, BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.Type: ApplicationFiled: December 2, 2009Publication date: April 1, 2010Applicant: IRM LLCInventors: Donatella Chianelli, Christopher Cow, Yun He, Songchun Jiang, Xiaolin Li, Xiaodong Liu, Zuosheng Liu, Jon Loren, Valentina Molteni, Juliet Nabakka, Pingda Ren, Taebo Sim, Xiaodong Wang, Shuli You
-
Patent number: 7678792Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR?, PDGFR?, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGF?, SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2?, BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.Type: GrantFiled: October 16, 2007Date of Patent: March 16, 2010Assignee: IRM LLCInventors: Donatella Chianelli, Christopher Cow, Yun He, Songchun Jiang, Xiaolin Li, Xiaodong Liu, Zuosheng Liu, Jon Loren, Valentina Molteni, Juliet Nabakka, Pingda Ren, Taebo Sim, Xiaodong Wang, Shuli You
-
Patent number: 7642255Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, c-Raf, Csk, Fes, FGFR, Flt3, Ikk, IR, JNK, Lck, Mkk, PKC, PKD, Rsk, SAPK, Syk, Trk, BTK, Src, EGFR, IGF, Mek, Ros and Tie2 kinases.Type: GrantFiled: April 8, 2008Date of Patent: January 5, 2010Assignee: IRM LLCInventors: Taebo Sim, Hyun Soo Lee, Pingda Ren, Qiang Ding, Yi Liu, Bing Li, Lintong Li, Xia Wang, Tetsuo Uno, Guobao Zhang, Nathanael Schiander Gray, Shuli You
-
Patent number: 7638523Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.Type: GrantFiled: October 31, 2007Date of Patent: December 29, 2009Assignees: IRM LLC, Novartis AGInventors: Valentina Molteni, Shuli You, Juliet Nabakka, Yi Liu, Xiaolin Li, Donatella Chianelli, Jon Loren, Xiaodong Liu, Shifeng Pan, Donald S. Karanewsky, Pascal Furet, Vito Guagnano
-
Publication number: 20090312321Abstract: Described are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent disease or disordered associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activity of kinases such as Abl, ALK, AMPK, Aurora, Axl, Bcr-Abl, BIK, Bmx, BRK, BTK, c-Kit, CSK, cSrc, CDK1, CHK2, CK1, CK2, CaMKII, CaMKIV, DYRK2, EGFR, EphB1, FES, FGFR1, FGFR2, FGFR3, Flt1, Flt3, FMS, Fyn, GSK3?, IGF-1R, IKK?, IKK?, IR, IRAK4, ITK, JAK2, JAK3, JNK1?1, JNK2?, KDR, Lck, LYN, MAPK1, MAPKAP-K2, MEK1, MET, MKK4, MKK6, MST2, NEK2, NLK, p70S6K, PAK2, PDGFR, PDGFR?, PDK1, Pim-2, Plk3, PKA, PKB?, PKC?, PKCtheta, PKD2, c-Raf, RET, ROCK-I, ROCK-II, Ron, Ros, Rsk1, SAPK2a, SAPK2b, SAPK3, SAPK4, SGK, SIK, Syk, Tie2, TrkB, WNK3, and ZAP-70.Type: ApplicationFiled: April 6, 2007Publication date: December 17, 2009Applicant: IRM LLCInventors: Pingda Ren, Guobao Zhang, Shuli You, Taebo Sim, Nathanael S. Gray, Yongping Xie, Xing Wang, Yun He
-
Publication number: 20090264649Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.Type: ApplicationFiled: May 29, 2009Publication date: October 22, 2009Applicants: IRM LLC, Novartis AGInventors: Valentina Molteni, Xiaolin Li, Donatella Chianelli, Jon Loren, Juliet Nabakka, Xiaodong Liu, Shifeng Pan, Yi Liu, Donald S. Karanewsky, Pascal Furet, Vito Guagnano, Shuli You
-
Patent number: 7592349Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.Type: GrantFiled: October 31, 2007Date of Patent: September 22, 2009Assignees: IRM LLC, Novartis AGInventors: Valentina Molteni, Shuli You, Juliet Nabakka, Yi Liu, Xiaolin Li, Donatella Chianelli, Jon Loren, Xiaodong Liu, Shifeng Pan, Donald S. Karanewsky, Pascal Furet, Vito Guagnano
-
Patent number: 7563894Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.Type: GrantFiled: October 31, 2007Date of Patent: July 21, 2009Assignees: IRM LLC, Novartis AGInventors: Valentina Molteni, Shuli You, Juliet Nabakka, Yi Liu, Xiaolin Li, Donatella Chianelli, Jon Loren, Xiaodong Liu, Shifeng Pan, Donald S. Karanewsky, Pascal Furet, Vito Guagnano
-
Publication number: 20090118273Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of Abl, Bcr-Abl, Bmx, BTK, b-RAF, c RAF, CSK, cSRC, Fes, FGFR3, Flt3, IKK?, IKK?, JNK1?1, JNK2?2, Lck, Met, MKK4, MKK6, p70S6K, PAK2, PDGFR?, PKA, PKC?, PKD2, ROCK-II, Ros, Rsk1, SAPK2?, SAPK2?, SAPK3, SAPK4, SGK, Syk, Tie2 and TrkB kinases.Type: ApplicationFiled: May 10, 2006Publication date: May 7, 2009Inventors: Advait Nagle, Nathanael Schiander Gray, Yi Liu, Pingda Ren, Taebo Sim, Shuli You
-
Publication number: 20090105250Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, FGFR3, PDGFR? and b-Raf kinases.Type: ApplicationFiled: January 19, 2006Publication date: April 23, 2009Applicant: IRM LLCInventors: Taebo Sim, Nathanael Schiander Gray, Hyun Soo Lee, Yi Liu, Pingda Ren, Shuli You, Qiong Zhang, Qiang Ding, Xia Wang, Songchun Jiang, Pamela A. Albaugh
-
Patent number: 7514447Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.Type: GrantFiled: September 26, 2006Date of Patent: April 7, 2009Assignees: IRM LLC, Novartis AGInventors: Valentina Molteni, Xiaolin Li, Donatella Chianelli, Jon Loren, Juliet Nabakka, Xiadong Liu, Shifeng Pan, Yi Liu, Donald S. Karanewsky, Pascal Furet, Vito Guagnano, Shuli You
-
Publication number: 20090012094Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.Type: ApplicationFiled: October 31, 2007Publication date: January 8, 2009Applicants: IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY, NOVARTIS, AGInventors: Valentina Molteni, Xiaolin Li, Donatella Chianelli, Jon Loren, Juliet Nabakka, Xiaodong Liu, Shifeng Pan, Yi Liu, Donald S. Karanewsky, Pascal Furet, Vito Guagnano, Shuli You
-
Patent number: 7449582Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, CSK, JNK1, JNK2, PDGF-R, p38, p70S6K, TGF?, SRC, EGFR, c-Kit, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6 and SAPK2? kinases.Type: GrantFiled: October 8, 2004Date of Patent: November 11, 2008Assignee: IRM LLCInventors: Qiang Ding, Yongping Xie, Nathanael S. Gray, Shuli You, Greg Chopiuk, Jiqing Jiang, Yi Liu, Ruo Steensma, Xing Wang, Taebo Sim
-
Publication number: 20080221098Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, c-Raf, Csk, Fes, FGFR, Flt3, Ikk, IR, JNK, Lck, Mkk, PKC, PKD, Rsk, SAPK, Syk, Trk, BTK, Src, EGFR, IGF, Mek, Ros and Tie2 kinases.Type: ApplicationFiled: April 8, 2008Publication date: September 11, 2008Applicant: IRM LLCInventors: Taebo Sim, Hyun Soo Lee, Pingda Ren, Qiang Ding, Yi Liu, Bing Li, Lintong Li, Xia Wang, Tetsuo Uno, Guobao Zhang, Nathanael Schiander Gray, Shuli You
-
Publication number: 20080176846Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR?, PDGFR?, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGF?, SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2?, BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.Type: ApplicationFiled: October 16, 2007Publication date: July 24, 2008Applicant: IRM LLCInventors: Donatella Chianelli, Christopher Cow, Yun He, Songchun Jiang, Xiaolin Li, Xiaodong Liu, Zuosheng Liu, Jon Loren, Valentina Molteni, Juliet Nabakka, Pingda Ren, Taebo Sim, Xiaodong Wang, Shuli You
-
Publication number: 20080167308Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.Type: ApplicationFiled: October 31, 2007Publication date: July 10, 2008Applicants: IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY, NOVARTIS, AGInventors: Valentina Molteni, Xiaolin Li, Donatella Chianelli, Juliet Nabakka, Jon Loren, Xiaodong Liu, Shifeng Pan, Yi Liu, Donald S. Karanewsky, Pascal Furet, Vito Guagnano, Shuli You